Last reviewed · How we verify

DA-5219 — Competitive Intelligence Brief

DA-5219 (DA-5219) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT4 receptor partial agonist. Area: Gastroenterology.

phase 3 5-HT4 receptor partial agonist 5-HT4 receptor Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

DA-5219 (DA-5219) — Dong-A ST Co., Ltd.. DA-5219 is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DA-5219 TARGET DA-5219 Dong-A ST Co., Ltd. phase 3 5-HT4 receptor partial agonist 5-HT4 receptor
Mosapride Citrate Tablets Mosapride Citrate Tablets Xiyuan Hospital of China Academy of Chinese Medical Sciences phase 3 5-HT4 receptor agonist 5-HT4 receptor
OPN-375 OPN-375 Optinose US Inc. phase 3 5-HT4 receptor agonist 5-HT4 receptor
S-268019-b S-268019-b Shionogi phase 3 5-HT4 receptor partial agonist 5-HT4 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT4 receptor partial agonist class)

  1. Dong-A ST Co., Ltd. · 1 drug in this class
  2. Shionogi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DA-5219 — Competitive Intelligence Brief. https://druglandscape.com/ci/da-5219. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: